Cagrilintide

Cagrilintide, usually called cagri, is a long-acting peptide that mimics amylin, a hormone involved in fullness. People discuss it for smaller meals and quieter food noise, often as an add-on to another weight-loss peptide. Experiences range from powerful suppression to no benefit, with fatigue and stomach problems sometimes outweighing the appeal.

A different fullness signal from GLP-1. Community explanations call it an amylin mimic: an extra meal-stop signal alongside incretin drugs. It acts at amylin and calcitonin receptors; its category placement does not make it a GLP-1 drug or a stimulant. Community Research: Cagrilintide with GLP1s (Secondhand community claim · Accessed 2026-09-30)

Injected under the skin; forms matter. SC means subcutaneous injection. Standalone powder-vial discussions, separate-drug injections and premixed blends describe different products. CagriSema pairs cagri with semaglutide; a research vial carrying that name is not the clinical product. Pramlintide is a different, shorter-acting amylin drug, with different amounts.

Source context — Community Research: Cagrilintide with GLP1s: A curated secondhand selection, with commercial supplier links and a sponsored-log link. Does not establish independent reports or safe stacks. Incorrect casual GIP/GLP-1 classification in a quoted log rejected.

Less food noise, or an earlier stopping point. Reports describe quieter cravings and becoming full after a few bites. That can make meals easier to stop, or leave people struggling to eat enough. Mental interest in food and physical fullness are different experiences. Taking cagrilintide alone (Community discussion · Accessed 2026-09-30) · Sleeeeepy (Community discussion · Accessed 2026-09-30)

Full after two bites can still leave temptation. A MESO user found that tradeoff disappointing. Another saw no benefit over six to eight weeks. A third credited a tirzepatide add-on with 20 lb lost over 2½ months, later pausing during a bodybuilding phase. These different histories do not establish causation. What are your experiences with Cagrilintide? — page 2 (Community discussion · Accessed 2026-09-30)

An add-on when progress stalls. Community accounts credit cagri alongside tirzepatide with renewed loss. Others gained weight or saw no suppression. Changing appetite, intake and another drug together prevents isolating cagri's contribution. I don’t feel it… (Community discussion · Accessed 2026-09-30)

Strong suppression, no suppression and fatigue can coexist. The mono thread includes enthusiastic reports without fatigue, exhaustion severe enough to stop, and four months without benefit up to 1 mg. Its title does not make every reply monotherapy: several explicitly include tirzepatide, and the poster later discloses lurasidone. Taking cagrilintide alone (Community discussion · Accessed 2026-09-30)

Fatigue is not explained just by eating too little. People argue about under-fueling versus a direct drug effect. Some recover after sleep or with continued use; others discontinue. The threads cannot settle that mechanism or identify a supplement that fixes it. Sleeeeepy (Community discussion · Accessed 2026-09-30) · Taking cagrilintide alone (Community discussion · Accessed 2026-09-30)

Source context — Taking cagrilintide alone: Thread mixes monotherapy and add-ons. User contraceptive assertions are not verified interaction evidence and are excluded. Posted date unavailable beyond relative timestamp; not inferred.

Source context — Sleeeeepy: Unverified personal accounts with co-use and inconsistent symptom courses. Preparation/storage advice in other replies excluded. Opened body shows relative times; date comes from search's absolute post stamp.

Source context — What are your experiences with Cagrilintide? — page 2: Anonymous bodybuilding users, other drugs and diets, unverified products. Site has commercial sponsorship. Not a prevalence sample; rat-energy-expenditure discussion in #26–28 is not adopted as a human outcome.

Source context — I don’t feel it…: Anonymous reports; products unverified, schedules differ, co-use and follow-ups mixed. No consensus, causal attribution or recommendation.

Low add-on reports: 0.125–0.25 mg SC weekly. Accounts include these amounts alongside high-dose incretins. One person reported 0.125 mg one week and 0.25 mg the next without benefit; another found 0.25 mg overwhelmingly suppressive. A low reported amount does not guarantee tolerability. I don’t feel it… (Community discussion · Accessed 2026-09-30)

Split reports: 0.1 mg twice weekly or 0.25 mg twice weekly. Those equal 0.2 mg or 0.5 mg per week, respectively. Both appear in discussions; fatigue and food aversion still occurred. A separate 0.25 mg twice-weekly account followed perceived day-3–4 fading, not measured clearance. Sleeeeepy (Community discussion · Accessed 2026-09-30) · When does a dose wear off? (Community discussion · Accessed 2026-09-30)

Higher reports and copied ladders are separate. A mono account reports 1 mg every five days. Circulated weekly charts copy 0.25 → 0.5 → 1 → 1.7 → 2.4 mg from trial schedules; commercial charts instead show 0.6 → 1.2 → 1.8/2.4 and sometimes 4.5 mg. These are different origins, not a recommended ladder. Taking cagrilintide alone (Community discussion · Accessed 2026-09-30)

Commercial cut charts: 0.5–1.2 versus 1.7–2.4 mg. These chart bands appear in short-block versus longer-cut discussion. They do not establish a useful cycle or a target for someone already getting strong suppression.

Source context — I don’t feel it…: Anonymous reports; products unverified, schedules differ, co-use and follow-ups mixed. No consensus, causal attribution or recommendation.

Source context — Sleeeeepy: Unverified personal accounts with co-use and inconsistent symptom courses. Preparation/storage advice in other replies excluded. Opened body shows relative times; date comes from search's absolute post stamp.

Source context — When does a dose wear off?: OP deleted; no original-body duration claim used. No reliable appetite offset supplied. Suggestions to double doses or substitute incretins are not adopted.

Source context — Taking cagrilintide alone: Thread mixes monotherapy and add-ons. User contraceptive assertions are not verified interaction evidence and are excluded. Posted date unavailable beyond relative timestamp; not inferred.

Within hours, next day, or two to three days. The onset thread contains those distinct personal answers. Two 0.25 mg add-on accounts describe just over two days and about three days. Other contributors feel nothing. The study's circulated 24–72-hour peak-concentration number is not a subjective onset clock. When does cagri appetite suppression kick in? (Community discussion · Accessed 2026-09-30) · What is the half-life of Cagrilintide? (Secondhand community claim · Accessed 2026-09-30)

Some notice a change only after several weeks. One commenter initially reported no effect at 2 mg, then said it was working in the third week. Amount, accumulation, co-use and expectations changed together; waiting longer does not guarantee eventual response. When does a dose wear off? (Community discussion · Accessed 2026-09-30)

Appetite can return around day 3–4 in some reports. That fading story sits alongside accounts using weekly or longer intervals. There is no dependable appetite-offset window in this sample. Circulated 2–4+ weeks of residual exposure is a half-life extrapolation, not observed weeks of appetite suppression. Taking cagrilintide alone (Community discussion · Accessed 2026-09-30)

Two tired days and four to five sick days are separate stories. One 0.5 mg account describes fatigue for the first two days. A different tirzepatide add-on report describes nausea, dry heaves and difficulty eating for four to five days. These are symptom durations, not a half-life or a prediction. Sleeeeepy (Community discussion · Accessed 2026-09-30) · First dose side effects (Community discussion · Accessed 2026-09-30)

159–195 hours: a human-study figure repeated online. A Reddit reply calls this about 7–8 days and links the phase 1b study with semaglutide. The exact conversion is about 6.6–8.1 days. This is trial-derived pharmacokinetics, not a measurement made by the commenter or proof of a research vial's contents. What is the half-life of Cagrilintide? (Secondhand community claim · Accessed 2026-09-30)

Nine days is a separate, unsupported claim. Another commenter says they read nine days without identifying the source. Neither figure tells us when hunger returns, fatigue ends or another injection is appropriate. What is the half-life of Cagrilintide? (Secondhand community claim · Accessed 2026-09-30)

lush_rational: 159–195 hours/about 7–8 days, then Lancet phase 1b abstract link and quotation including Tmax 24–72 hours. Emmasmom5: read nine days, no source. What is the half-life of Cagrilintide? (Secondhand community claim · Accessed 2026-09-30)

Source context — When does cagri appetite suppression kick in?: Mixed drugs and timing, unverified products and an autoimmune-disease fatigue confound. OP's secondhand onset range distinguished from replies. No sourcing or self-adjustment suggestions retained.

Source context — What is the half-life of Cagrilintide?: Forum repeats a human combination-trial measurement, not user-measured kinetics. Current linked Lancet and PubMed abstract retrieval failed. Nine-day origin unknown; personal frequency choice not adopted.

Source context — When does a dose wear off?: OP deleted; no original-body duration claim used. No reliable appetite offset supplied. Suggestions to double doses or substitute incretins are not adopted.

Source context — Taking cagrilintide alone: Thread mixes monotherapy and add-ons. User contraceptive assertions are not verified interaction evidence and are excluded. Posted date unavailable beyond relative timestamp; not inferred.

Source context — Sleeeeepy: Unverified personal accounts with co-use and inconsistent symptom courses. Preparation/storage advice in other replies excluded. Opened body shows relative times; date comes from search's absolute post stamp.

Source context — First dose side effects: Tirzepatide total conflicts with the comment's every-five-day description, so no tirzepatide weekly total inferred. Several operational or unit-ambiguous replies excluded. No benefit or harm rate.

Weeks to months; no established community cycle. One account continued 0.25 mg with tirzepatide for two months before increasing. Another stopped after four months without suppression. These personal calendars do not define an effective on/off schedule. When does cagri appetite suppression kick in? (Community discussion · Accessed 2026-09-30) · Taking cagrilintide alone (Community discussion · Accessed 2026-09-30)

Eight weeks on/eight off is commercial-chart talk. Community discussions also describe ongoing lower-amount maintenance and concern about returning to a former high amount after a gap. No inspected evidence validates a reset, rebound-prevention or restart formula. Trial lengths are study follow-up periods, not peptide cycles.

Source context — When does cagri appetite suppression kick in?: Mixed drugs and timing, unverified products and an autoimmune-disease fatigue confound. OP's secondhand onset range distinguished from replies. No sourcing or self-adjustment suggestions retained.

Source context — Taking cagrilintide alone: Thread mixes monotherapy and add-ons. User contraceptive assertions are not verified interaction evidence and are excluded. Posted date unavailable beyond relative timestamp; not inferred.

CagriSema (primary clinical stack): Fixed-dose cagrilintide 2.4 mg + semaglutide 2.4 mg once weekly after paired 1:1 titration — main RCT and forum reference stack. [trial]

DIY cagri + sema (separate vials): Community mirrors 1:1 mg steps toward 2.4/2.4; dose match, purity, and sterility are uncontrolled vs trial pens. [community]

Stack ratios are claims about different mixtures. Talk includes 1:1 cagri/sema, 5:1 reta/cagri premixes and a claimed 2:1–4:1 reta/cagri preference. That account's examples—2–3 mg reta with 0.25–0.5 mg cagri—actually imply 4:1–12:1. No ratio is validated by those stories.

Same-day and mid-week add-ons both appear. Reports describe same-day tirzepatide pairing and a 3½-day separation. Other accounts describe stabilizing tirzepatide for about eight weeks, or retatrutide for eight to twelve, before an add-on. These histories explain attribution concerns; they establish no superior sequence. First dose side effects (Community discussion · Accessed 2026-09-30)

Cagri + retatrutide: Theoretical five-pathway stack (amylin + GLP-1/GIP/glucagon); community often adds cagri only after reta is tolerated around ~2 mg; zero completed combo RCTs. [community]

Source context — First dose side effects: Tirzepatide total conflicts with the comment's every-five-day description, so no tirzepatide weekly total inferred. Several operational or unit-ambiguous replies excluded. No benefit or harm rate.

Fullness can become inability to eat or drink. Reports include diarrhea, sulphur burps, vomiting and severe drowsiness, even at low reported amounts. Persistent vomiting, inability to keep fluids down or severe abdominal pain calls for prompt medical assessment; eating less is not automatically a good outcome. First dose side effects (Community discussion · Accessed 2026-09-30) · Taking cagrilintide alone (Community discussion · Accessed 2026-09-30)

Fatigue is not explained just by eating too little. People argue about under-fueling versus a direct drug effect. Some recover after sleep or with continued use; others discontinue. The threads cannot settle that mechanism or identify a supplement that fixes it. Sleeeeepy (Community discussion · Accessed 2026-09-30) · Taking cagrilintide alone (Community discussion · Accessed 2026-09-30)

A blend can hide identity and amount errors. Reports describe clouding, stability concerns, wrong-peptide labels and concentration mistakes. A purity claim does not establish sterility or compatibility. No preparation, storage or syringe recipe follows from these anecdotes.

Oral medicines and procedures add uncertainty. Delayed stomach-emptying concerns appear in interaction and surgery discussions. These accounts cannot settle absorption or contraceptive effectiveness, and do not establish use in pregnancy or children. Taking cagrilintide alone (Community discussion · Accessed 2026-09-30)

Investigational status matters. FDA states that cagrilintide is not a component of an approved drug and cannot be used in compounding under federal law. A research-use label does not supply clinical authorization or safety assurance. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (Official context · Accessed 2026-09-30)

Source context — First dose side effects: Tirzepatide total conflicts with the comment's every-five-day description, so no tirzepatide weekly total inferred. Several operational or unit-ambiguous replies excluded. No benefit or harm rate.

Source context — Taking cagrilintide alone: Thread mixes monotherapy and add-ons. User contraceptive assertions are not verified interaction evidence and are excluded. Posted date unavailable beyond relative timestamp; not inferred.

Source context — Sleeeeepy: Unverified personal accounts with co-use and inconsistent symptom courses. Preparation/storage advice in other replies excluded. Opened body shows relative times; date comes from search's absolute post stamp.

Source context — FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss: U.S. regulatory context, not global legal advice, not a cagrilintide safety study. Broader semaglutide/tirzepatide adverse-event counts not transferred to cagri.